C

ConvaTec Group

Develops medical devices for chronic care

Team Leader - CRM Operations, Governance & Reporting

Full-TimeUpdated on 10/23/2026
No salary listed
Mid
Bachelor's
Lisbon, Portugal
HybridHybrid work; ATS workplace is Lisbon, Portugal.
IT OperationsEnterprise Applications

About the job

Requirements
  • A degree in Business, Information Systems, Data Analytics, or a related discipline.
  • Significant experience supporting CRM operations, reporting, commercial excellence, or sales effectiveness functions.
  • Experience leading teams within a shared services, global business services, commercial operations, or sales support environment.
  • Experience working with Microsoft Dynamics CRM and reporting platforms.
  • A proven track record of stakeholder management across commercial, information technology, and business leadership teams.
  • Experience delivering process improvements, transformation initiatives, and operational excellence programmes.
  • Demonstrated ability to lead commercial reporting transformation, automation, or digital initiatives.
  • Strong knowledge of Microsoft Dynamics CRM administration, governance, and operational support.
  • Strong understanding of commercial processes, sales effectiveness, and CRM operating models.
  • Experience leading CRM support, reporting, or shared services teams.
  • Strong understanding of data governance, quality management, and compliance requirements.
  • Experience managing service delivery, service-level agreements, key performance indicators, and operational performance.
  • Experience working within global or regional matrix organisations.
  • Commercial data literacy.
  • Key performance indicator governance.
  • A data product mindset.
  • Ability to translate commercial business requirements into scalable analytical solutions.
  • Strong people leadership and coaching capability.
  • A customer-focused approach and strong service delivery mindset.
  • Strong stakeholder management and influencing skills.
  • Strategic thinking and strong operational execution capability.
  • A solutions-oriented approach and continuous improvement mindset.
  • Strong planning, prioritisation, and organisational skills.
  • Ability to navigate ambiguity and lead through change.
  • Strong accountability and ownership mindset.
  • Collaboration, courage, and resilience in a complex stakeholder environment.
  • Curiosity and willingness to use data-driven innovation to improve commercial capabilities.
Responsibilities
  • Lead, coach, and develop a team responsible for CRM operations, reporting, user support, and data governance activities.
  • Establish objectives, priorities, performance measures, and development plans for team members.
  • Monitor team workload, capacity, and service delivery performance to ensure service-level commitments are achieved.
  • Create a customer-focused culture that delivers quality, accuracy, and responsiveness.
  • Drive employee engagement, capability development, and succession planning within the team.
  • Ensure effective knowledge management, process documentation, and cross-training across the team.
  • Own operational delivery of Microsoft Dynamics CRM support services across the European Commercial organisation.
  • Ensure CRM configuration, workflows, user access, security roles, and business rules are effectively managed and maintained.
  • Lead management of CRM incidents, service requests, escalations, and enhancement demands.
  • Act as the senior escalation point for complex system issues and business-critical incidents.
  • Monitor CRM system performance, user adoption, and service effectiveness across supported markets.
  • Lead production and delivery of standardised and ad hoc commercial reporting across Europe.
  • Ensure reporting outputs provide timely, accurate, and actionable business insights.
  • Work with Business Intelligence and Analytics teams to contribute to the development and maintenance of CRM dashboards, scorecards, key performance indicators, and management reporting.
  • Drive standardisation of reporting methodologies, definitions, and governance across markets.
  • Partner with Commercial Excellence and Sales Leadership to identify reporting requirements and support business decision-making.
  • Promote automation and simplification of reporting processes through Power BI, Power Automate, and other digital solutions.
  • Define and govern commercial key performance indicator definitions and reporting standards across European markets.
  • Prioritise reporting requirements with Commercial Excellence and the Commercial Intelligence Analytics and Business Intelligence Team.
  • Ensure business definitions and reporting rules are consistently applied across CRM reporting.
  • Establish and maintain CRM data governance standards, controls, and operating procedures.
  • Ensure data completeness, integrity, consistency, and compliance across supported markets.
  • Lead regular audits, data quality reviews, and corrective action plans.
  • Define and monitor data quality key performance indicators and reporting metrics.
  • Partner with Commercial, Compliance, and Data Privacy teams to ensure adherence to governance requirements.
  • Drive continuous improvement initiatives to enhance data quality and system effectiveness.
  • Own the business glossary and standard business definitions for CRM operational reporting.
  • Ensure CRM data structures support reusable analytics and future artificial intelligence-enabled capabilities.
  • Serve as the primary operational interface between the European Commercial Centre of Excellence and the CRM Operations and Reporting team.
  • Build relationships with Commercial Excellence, Sales Leadership, Marketing, Business Unit stakeholders, and Global Centre of Excellence teams.
  • Translate business requirements into scalable CRM and reporting solutions.
  • Provide recommendations and insights to support commercial effectiveness, customer engagement, and sales performance.
  • Represent CRM Operations and Reporting in governance forums, leadership meetings, and transformation initiatives.
  • Review stakeholder expectations regularly and align them with service delivery objectives.
  • Act as the primary business partner to the Commercial Intelligence Analytics and Business Intelligence Team for prioritisation of reporting capabilities and operational data requirements.
  • Drive continuous improvement initiatives focused on service quality, efficiency, automation, and user experience.
  • Lead implementation of new CRM capabilities, reporting enhancements, and process optimisation opportunities.
  • Support commercial transformation programmes and digital initiatives affecting CRM and reporting processes.
  • Identify opportunities to standardise ways of working across European markets through enhanced data products, automation, and emerging artificial intelligence capabilities.
  • Foster a culture of innovation and operational excellence within the team.
  • Ensure CRM and reporting processes comply with company policies, the General Data Protection Regulation, and regulatory requirements.
  • Maintain robust controls for CRM access management, data integrity, and reporting accuracy.
  • Support internal and external audits and ensure remediation actions are completed effectively.
  • Maintain documentation, audit evidence, process maps, and control records.
  • Mitigate operational risks through effective governance and control frameworks.
  • Lead and develop a team of CRM Analysts.
  • Manage team performance, development, coaching, and succession planning.
  • Foster collaboration, accountability, and continuous learning within the team.
  • Ensure team capability aligns with evolving CRM and reporting needs.
  • Champion Convatec values and leadership behaviours.
Desired Qualifications
  • Previous experience in the healthcare industry is highly preferred and considered a strong advantage.

About the company

C

ConvaTec Group

View
Website

Convatec Group provides medical devices and services for chronic care. It designs, manufactures, and distributes products across wound care, ostomy care, continence care, and infusion care for patients and healthcare providers in nearly 100 countries. Its products aim to prevent infection, protect the skin, and support safer, easier patient care, while helping health systems lower overall costs. A notable example is the compact catheter for women, which combines discreet use with reliable protection. The company employs about 10,000 people and operates under a commitment to ongoing, reliable care—’forever caring’—to meet evolving patient and system needs. The goal is to improve patient outcomes and reduce the total cost of care through clinically and economically beneficial medical devices and services.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1978

Get referred to ConvaTec Group

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 28, 2026 Cure Aqua launch expands North American catheter choice immediately.
  • H1 2026 organic revenue grew 5.0% excluding InnovaMatrix, with 21.2% adjusted operating margin.
  • Rhymney’s £24 million expansion and £200 million buyback support growth, margins, and returns.

What critics are saying

  • Parsons v Convatec Limited seeks up to £366 million; trial is listed for 2027.
  • InnovaMatrix collapsed after CMS cut Medicare reimbursement by over 85% on January 1, 2026.
  • Tandem Diabetes Care faces a September 18, 2026 product-liability complaint naming Convatec as defendant.

What makes ConvaTec Group unique

  • Convatec sells chronic-care devices across wound, ostomy, continence, and infusion care in 90+ countries.
  • Its me+ support program and user-centered launches like Cure Aqua deepen switching costs.
  • Hydrofiber and Aquacel remain durable platforms, with 1.5 billion dressings sold worldwide.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours

Company News

The Montreal Gazette
Oct 22nd, 2026
Convatec recognized with two prestigious Vizient(R) supplier Excellence Awards.

Convatec recognized with two prestigious Vizient(R) supplier Excellence Awards. Convatec honored as Non-Acute Supplier of the Year and recipient of Medical and Surgical Excellence Award BOSTON - Convatec, a leading medical products and technologies company focused on solutions for the management of chronic conditions, announced it has been recognized by Vizient(R), the largest provider-driven healthcare performance improvement company in the United States, with two... October 22, 2026 at 8:27 a.m. Convatec honored as Non-Acute Supplier of the Year and recipient of Medical and Surgical Excellence Award BOSTON - Convatec, a leading medical products and technologies company focused on solutions for the management of chronic conditions, announced it has been recognized by Vizient(R), the largest provider-driven healthcare performance improvement company in the United States, with two distinguished supplier awards, including 2026 Non-Acute Supplier of the Year and 2026 Medical and Surgical Excellence Award. The awards were presented at the Vizient(R) Connections Summit 2026 in Las Vegas, Nevada, and recognize suppliers that demonstrate exceptional performance, customer commitment, innovation, and value creation for healthcare providers across the United States. These awards recognise the clinical value, service excellence and trusted relationship Convatec delivers to healthcare providers across acute and non-acute care settings. The recognition was driven by Convatec's performance in Advanced Wound Care, Ostomy Care and Bowel Management, where the company continues to deliver meaningful value to healthcare providers through innovative solutions, trusted support, and a focus on improving patient outcomes. Gary Holder, Vice President, Corporate Accounts, Convatec, said: "Receiving both the Non-Acute Supplier of the Year and Medical and Surgical Excellence Awards is a tremendous honor and reflects the strength of our relationship with Vizient and its member organizations. We are especially proud that this recognition reflects the value our Advanced Wound Care, Ostomy Care, and Bowel Management portfolios deliver to healthcare providers, as well as the dedication of our colleagues who work every day to help improve outcomes for patients." Vizient's diverse client base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute healthcare providers and represents more than $156 billion in annual purchasing volume. Vizient's supplier recognition program evaluates organizations based on customer service, innovation, operational excellence, and their ability to support member healthcare systems in achieving improved performance. Convatec earned these honors in competition with several leading healthcare companies, demonstrating the company's growing impact and trusted position within the healthcare ecosystem. Simrit Sandhu, president, spend management, Vizient, said: "Congratulations to Convatec on receiving the 2026 Non-Acute Supplier of the Year and Medical and Surgical Excellence Awards. This recognition reflects the company's commitment to supporting Vizient clients as they work to optimize performance, manage costs and strengthen the healthcare supply chain." The awards build on Convatec's recent momentum in strengthening relationships with major healthcare organizations, further reflecting the company's focus on delivering innovative solutions, responsive support, and long-term value across the continuum of care. About Convatec Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care and Infusion Care. With over 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and treatment for hard-to-heal wounds, at-risk skin and ulcerated tissue to support for debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2025 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more, please visit http://www.convatecgroup.com.

MedTech Dive
Oct 5th, 2026
After years-long turnaround, Convatec's new CEO plans R&D push.

After years-long turnaround, Convatec's new CEO plans R&D push. Jonny Mason, who became CEO of the medtech firm a year ago following the death of Karim Bitar, said Convatec's pace of launching new devices has accelerated for 2026 and 2027. Published Oct. 5, 2026 As Convatec completes a multiyear effort to turn around the business, new CEO Jonny Mason plans to invest in research and development for future growth. The London-based medtech firm, which specializes in infusion care, wound care, ostomy care and continence, announced plans last year to expand its Boston-based R&D facility by 50%, and open a new facility in Manchester, England. Former CEO Karim Bitar joined Convatec in 2019 to develop a turnaround strategy for the company, which had struggled with profit warnings and a falling share price since it started trading on the London Stock Exchange. That plan involved focusing on Convatec's strengths, doubling its R&D investment and upping capital spending to rebuild its factories. Unfortunately, Bitar died suddenly last October while on medical leave. Mason, who joined Convatec in 2022 as CFO, has taken on Bitar's legacy after being named CEO in October. The turnaround is complete, Mason said, and Convatec is now aiming for sales growth of 6% to 8% next year, supported by a series of new product launches in each of its categories. MedTech Dive spoke with Mason about what's next for the company and its investment plans. Editor's note: This interview has been edited for length and clarity. MEDTECH DIVE: What are your top priorities as CEO? Is it a continuation of your work with Karim? Has anything changed? JONNY MASON: Something has changed, which is that we've increased our ambition. Karim very successfully took us through the turnaround strategy, and we acknowledged that the turnaround was complete last year. So it was time to step up a level. What Convatec is trying to do now is more than it's ever done before. We are launching more products in 2026 than we've ever done before. We're investing more capital. We're increasing capacity in our factories. So all of that requires the whole Convatec organization to execute more effectively, and to live and breathe a culture of purpose and performance. What segments do you see the most growth in for Convatec? All four of our categories are going to grow faster next year than they did this year because we're launching new products in all of those categories. But if you were to push me, infusion care is where our business is growing fastest, and that's because pump therapy is expanding in its treatment of patients, both in diabetes and also in Parkinson's disease. We're the world leader in the manufacture of infusion sets. The use of pump therapy as opposed to pills or multiple daily injections is increasing quickly around the world. So that piece of our business, we expect that to grow in double digits from next year onwards. What are some new devices to watch for? In [the infusion care] space, the most exciting thing is Parkinson's disease at the moment. AbbVie launched their Parkinson's therapy a couple of years ago, and that's growing really fast. And we are the exclusive supplier of infusion sets to them. But coming now are two other suppliers of Parkinson's disease therapies: Supernus and Mitsubishi Tanabe. We will be launching with them the infusion sets to support their Parkinson's therapy. Beyond that in infusion care, in a few years' time, we're working on higher volume and higher viscosity infusion sets, which will enable things like chemotherapy and/or pain relief to be treated with pump therapy. We launched a new product only yesterday [September 28] in the U.S. market, and this was an intermittent catheter called Cure Aqua. It's made of a hydrophilic polymer, which is friction free with just the application of water, and it's ready to use and it's in the value end of the market. So this is a product which is going to make life much better for a number of catheter users in the U.S. We launched eight new products between 2022 and 2025. And then in 2026 and 2027, we're doing eight more. So the pace of launch is accelerating. At the start of the year, the FDA had raised concerns with infusion sets made by subsidiary Unomedical in a warning letter. Do you have any updates on that? We are making good progress. We are in a very constructive dialog with the FDA. We understand exactly what their observations are. The observations did not relate to product quality nor to patient safety, and therefore they have not impacted our sales or our production at all. What they observed was that they said we weren't managing our complaints process well enough, and we accept that entirely. We're working with them to change it. They said the same thing, by the way, to various other operators within the diabetes sector. We're working constructively with them, making good progress. The nature of these things is that they take time, so we would like to think that we can get through all of this by the end of 2027.

Business Wire
Sep 28th, 2026
Convatec launches Cure Aqua ready-to-use catheter in US and Canada

Convatec has launched Cure Aqua™, a ready-to-use hydrophilic intermittent catheter, in the United States and Canada. The product expands the company's Cure™ catheter portfolio and was developed with input from people who catheterise. Cure Aqua™ features a hydrophilic coating for low-friction use, a no-touch handling sleeve, fire-polished eyelets, and easy-open packaging. It is available in female, male, and paediatric options. The catheter contains no DEHP/DINP, BPA, or natural rubber latex. The Boston and London-based medical products company focuses on solutions for chronic condition management. Convatec also plans to launch GentleCath Air Pocket™ and GentleCath Air Set™ in Europe later this year. The company reported revenues exceeding $2 billion in 2025.

Benzinga
Sep 28th, 2026
Convatec expands Cure(TM) portfolio with launch of Cure Aqua(TM), bringing greater choice to people who catheterize.

Convatec expands Cure(TM) portfolio with launch of Cure Aqua(TM), bringing greater choice to people who catheterize. * New ready-to-use hydrophilic catheter designed to make self-catheterization a smaller part of everyday life, launching initially across the US and Canada in September, with other markets to follow. Convatec, a leading medical products and technologies company focused on solutions for the management of chronic conditions, announces the launch of Cure Aqua(TM) in the United States and Canada. The latest addition to Convatec's Cure(TM) catheter portfolio, Cure Aqua(TM) is a ready-to-use hydrophilic intermittent catheter designed to support a comfortable catheterization experience while helping simplify daily routines. Developed with direct input from people who catheterize, Cure Aqua(TM) combines user-centered design with practical, comfort-focused features to help make self-catheterization a smaller part of everyday life. Cure Aqua(TM) is ready to use with no activation step required[1]. Key features[1] include: * A hydrophilic coating designed for a comfortable, low-friction catheterization experience * A no-touch handling sleeve to help reduce contamination risk * Unique fire-polished eyelets designed for comfortable insertion * Easy-open packaging and an opaque design for greater privacy * Materials free from DEHP/DINP, BPA and natural rubber latex * Distinctive blue control stripe, a well-recognized feature across the Cure portfolio that supports proper Coudé-tip orientation during use Cure Aqua(TM) is available in female, male and pediatric options, providing choice across a range of patient needs, lifestyles and preferences. Mark Jassey, President, Continence Care & Home Services Group, said: "At Convatec, we believe the most impactful innovation starts with understanding the experiences of the people we serve and ensuring we provide meaningful choice to reflect individual needs and lifestyles. The launch of Cure Aqua(TM) is another step in expanding access to solutions that help people self-catheterize with greater confidence and independence, while advancing our vision: Pioneering trusted medical solutions to improve the lives we touch." The launch of Cure Aqua(TM) further strengthens Convatec's Cure(TM) catheter portfolio of innovative, user-centered continence care solutions. Founded by a catheter user, the Cure(TM) brand has long focused on delivering solutions designed around the people who use them. The addition of Cure Aqua(TM) expands choice for healthcare professionals and users, helping ensure more people across North America find a solution that fits their individual needs, preferences and lifestyles. As Convatec continues to advance its strongest innovation pipeline in its history, the company remains focused on delivering trusted medical solutions to more people, including the planned launch of GentleCath Air Pocket(TM)& GentleCath Air Set(TM) in Europe expected later this year. Beyond innovative products, Convatec supports people through me+, its personalized support program designed to help people living with chronic health conditions with practical, social and emotional guidance, compassionate care, and meaningful connection to help individuals navigate every stage of their journey. Together, products and services like me+ reflect Convatec's forever caring promise, helping people live with greater confidence while improving experiences and outcomes. References 1. Data on file About Convatec Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care and Infusion Care. With over 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and treatment for hard-to-heal wounds, at-risk skin and ulcerated tissue to support for debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2025 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more, please visit http://www.convatecgroup.com. AP-82066-GBL-ENG-v2

Fortune Business Insights
Sep 4th, 2026
Diabetic Foot Ulcer Treatment Market to grow at a CAGR of 7.01% from 2026 to 2034; rising incidence of DFUs is propelling Market Growth.

Diabetic Foot Ulcer Treatment Market to grow at a CAGR of 7.01% from 2026 to 2034; rising incidence of DFUs is propelling Market Growth. September 04, 2026 | Healthcare The global diabetic foot ulcer treatment market size was valued at USD 7.14 billion in 2025. The market is expected to grow from USD 7.53 billion in 2026 to USD 12.46 billion by 2034, exhibiting a CAGR of 6.5% during the forecast period. Fortune Business Insights(TM) presents this information in its report titled "Diabetic Foot Ulcer Treatment Market Size, Share & Industry Analysis, By Ulcer Type (Neuropathic Ulcers, Ischemic Ulcers, and Neuro-Ischemic Ulcers), By Product (Wound-Care Dressings [Antimicrobial Dressings, Foam Dressings, and Hydrogel Dressings], Wound-Care Devices [Negative Pressure Wound Therapy, Ultrasound Therapy, and Hyperbaric Oxygen Therapy], and Active Therapies [Skin Grafts & Substitutes and Growth Factors]), By Severity (Mild, Moderate, and Severe), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Homecare Settings, and Others), and Regional Forecast, 2026-2034". Diabetic Foot Ulcers (DFUs) are chronic wounds that affect individuals with both type 1 and type 2 diabetes. They represent a serious complication of diabetes and are generally characterized by wounds on the feet that heal slowly or fail to heal completely. Without timely and effective treatment, DFUs may progress to severe infections and, in advanced cases, result in lower-limb amputation. DFU care encompasses a broad spectrum of treatment products and therapies designed to promote wound healing, prevent infection, and reduce ulcer-related complications. These include advanced wound dressings such as antimicrobial & hydrogel dressings and devices such as negative pressure wound therapy (NPWT), Hyperbaric Oxygen Therapy (HBOT), and active therapies such as skin graft substitutes. Offloading devices are also widely used to minimize pressure on affected areas and support healing. The rising prevalence of DFUs among the growing diabetic population is expected to increase demand for these treatment solutions, thereby supporting market expansion. Convatec Announced Completion of a Significant Multi-year Expansion at Its Rhymney Production Unit In July 2026, Convatec, a renowned medical product and technology company specializing in solutions for the management of chronic conditions, announced the successful completion of a multi-year expansion project at its manufacturing facility in Rhymney, South Wales. The company invested more than USD 27.1 million in the expansion, aimed at strengthening the site's manufacturing capabilities and supporting the growing demand for advanced healthcare products. Growing Prevalence of Diabetes Fosters Market Growth The mounting diabetes burden globally is a primary factor driving the increasing incidence of diabetic foot ulcers, one of the most serious complications associated with the disease. The expanding geriatric population, sedentary lifestyles, dietary changes, and rising obesity rates are contributing to the global diabetes burden. Moreover, clinical evidence indicates that individuals with diabetes are substantially more likely to develop foot ulcers than non-diabetic individuals, further intensifying the need for effective treatment options. For instance, an article published in the International Wound Journal in 2023 reported that diabetic foot ulcers have a global prevalence of approximately 6.3% based on available studies assessing their global epidemiology. Technological innovations in diabetic foot ulcer treatment management are encouraging the development and uptake of smart wound dressings. Leading companies are increasing their investments in R&D to introduce innovative products with enhanced monitoring and healing capabilities, thereby supporting the global diabetic foot ulcer treatment market growth. On the other hand, the low rates of wound diagnosis and treatment across emerging countries are impeding diabetic foot ulcer treatment demand. Major Players Emphasize Product Portfolio Expansion to Support Their Dominance Leading diabetic foot ulcer treatment companies are maintaining their market dominance through broad product portfolios, strategic acquisitions, collaborations, and other inorganic growth initiatives implemented across various regions. Smith+Nephew and Solventum hold prominent positions in the market, driven by their extensive offerings and strong global footprint. In addition, the rising emphasis on R&D is encouraging companies to launch technologically advanced and differentiated wound care products, thereby strengthening their market presence. * In April 2024, Smith+Nephew introduced its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System in the U.S., providing a patient-focused option for managing chronic wounds. List of Key Players Mentioned in the Report * Coloplast A/S (Denmark) * Smith+Nephew (U.K.) * Solventum (U.S.) * Convatec Inc. (U.K.) * Integra LifeSciences (U.S.) * Braun SE (Germany) * Cardinal Health (U.S.) * Mölnlycke Health Care AB (Sweden) * Essity Aktiebolag (publ). (Sweden) * MIMEDX Group, Inc. (U.S.) Key Industry Development * April 2024: Smith+Nephew reported that the U.K. National Institute for Health and Care Excellence (NICE) reviewed its PICO Single Use Negative Pressure Wound Therapy System (sNPWT). NICE concluded that the system delivers improved clinical outcomes compared with standard dressings in decreasing the risk of surgical site infections. Further Report Findings * North America maintained its position as the leading regional market, reaching USD 2.65 billion in 2024 and increasing to USD 2.78 billion in 2025. The widespread adoption of advanced wound-care products, well-developed hospital infrastructure, and rising healthcare expenditure supports the region's strong market position. * Europe is predicted to expand at a CAGR of 6.2% over the forecast period, representing the second-fastest growth among regions, and is projected to reach USD 2.05 billion in 2026. Increasing diabetic population, combined with the region's advanced healthcare infrastructure, is anticipated to accelerate market expansion. * Based on ulcer type, neuro-ischemic ulcers accounted for the largest diabetic foot ulcer treatment market share in 2025. The rising incidence of neuro-ischemic ulcers among diabetic patients is increasing the need for specialized treatment solutions. Furthermore, the introduction of innovative wound-care products, skin substitutes, and NPWT technologies by prominent companies is likely to create additional growth opportunities for this segment. * By product, wound-care dressings led the market in 2025 due to their effectiveness and versatility in managing DFUs. Leading producers are intensifying R&D efforts to develop more advanced dressing technologies, providing further momentum to the segment. Table of Segmentation | ATTRIBUTE | DETAILS | | Study Period | 2021-2034 | | Base Year | 2025 | | Estimated Year | 2026 | | Forecast Period | 2026-2034 | | Historical Period | 2021-2024 | | Unit | Value (USD billion) | | Growth Rate | CAGR of 6.5% from 2026 to 2034 | | Segmentation | By Ulcer Type, Product, Severity, End User, and Region | | By Ulcer Type | * Neuropathic Ulcers * Ischemic Ulcers * Neuro-ischemic Ulcers | | By Product | * Wound-care Dressings * Antimicrobial Dressings * Foam Dressings * Film Dressings * Alginate Dressings * Hydrogel Dressings * Other Dressings * Wound-care Devices * Negative Pressure Wound Therapy (NPWT) * Ultrasound Therapy * Hyperbaric Oxygen Therapy (HBOT) * Others * Active Therapies * Skin Grafts & Substitutes * Growth Factors * Others * Others | | By Severity | * Mild * Moderate * Severe | | By End User | * Hospitals * Clinics * Ambulatory Surgical Centers * Homecare Settings | | By Region | * North America (By Ulcer Type, By Product, By Severity, By End User, and By Country) * U.S. * Canada * Europe (By Ulcer Type, By Product, By Severity, By End User, and By Country/Sub-Region) * U.K. * Germany * France * Spain * Italy * Scandinavia * Rest of Europe * Asia Pacific (By Ulcer Type, By Product, By Severity, By End User, and By Country/Sub-Region) * Japan * China * India * Australia * Southeast Asia * Rest of Asia Pacific * Latin America (By Ulcer Type, By Product, By Severity, By End User, and By Country/Sub-Region) * Brazil * Mexico * Rest of Latin America * Middle East & Africa (By Ulcer Type, By Product, By Severity, By End User, and By Country/Sub-Region) * GCC * South Africa * Rest of Middle East & Africa | * PDF * 2025 * 2021 - 2024 * 160 Choose license Type * 4850 5850 6850.